Latest / Inside Startup Investing with Chris Lustrino
How Sen-Jam Is Building a Portfolio of Inflammation Drugs
In this episode of Inside Startup Investing, Chris Lustrino speaks with Jim Iversen, CEO of Sen-Jam Pharmaceutical, about building a platform of therapeutics targeting inflammation across multiple diseases. (00:00–01:28)
The company is advancing a pipeline of drugs addressing conditions like COVID, alcohol-related inflammation, and arthritis, with multiple Phase 2 trials completed. (01:28–02:27)
Jim explains how drug development works—from preclinical research to Phase 1 (safety), Phase 2 (efficacy), and Phase 3 (confirmatory trials). (04:14–06:05)
They explore how Sen-Jam uses AI and over…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.